TABLE 2.
The characteristics of patients.
| Study, year | Female (%) | BMI (kg/m2) | Mean age, years | Adherence to TRE | Antidiabetic drugs |
| Arnason and Kerry (19) | 90% | 36.9 ± 8.29 | 53.8 ± 9.11 | 80% adherent to TRE | Metformin; gliclazide; liraglutide. |
| Andriessen et al. (12) | 50.00% | 30.5 ± 3.7 | 67.5 ± 5.2 | 100% to TRE and control | Metformin only; metformin, gliclazide; others |
| Chair et al. (15) | 63.30% | 26.7 ± 2.0 | 35.2 ± 6.2 | 97% adherent to ADF; 100% adherent to TRE and control | None |
| Che et al. (11) | 45.80% | 26.3 ± 2.1 | 48.5 ± 9.4 | 90% adherent to TRE and 83.3% to control | OHA; insulin |
| Kahleova et al. (16) | 46% | 32.6 ± 4.9 | 59.4 ± 7.0 | 88.9% adherent to TRE and 85.2% to control | Metformin; DPP-4 inhibitors; sulfonylurea; glinides; thiazolidinedione; acarbose |
| Parr et al. (17) | 52.60% | 34.0 ± 5.0 | 50.0 ± 9.0 | 72% adherent to TRE | Metformin; SGLT-2 inhibitors; DPP-4 inhibitors |
| Sutton et al. (18) | 0 | 32.2 ± 4.4 | 56.0 ± 9.0 | 100% to TRE and 98.9% to control | None |
TRE, Time-restricted eating; ADF, Alternate-day Fasting; OHA, Oral hupoglycemic agents; DPP-4, Dipeptidyl peptidase-4; SGLT-2, Sodium-dependent glucose transporters 2.